Dennis Kannenkeril
Friedrich-Alexander-Universität Erlangen-Nürnberg(DE)Royal Perth Hospital(AU)Universitätsklinikum Erlangen(DE)Comprehensive Cancer Center Erlangen(DE)
Publications by Year
Research Areas
Blood Pressure and Hypertension Studies, Cardiovascular Health and Disease Prevention, Diabetes Treatment and Management, Retinal Imaging and Analysis, Cardiovascular Function and Risk Factors
Most-Cited Works
- → SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial(2018)180 cited
- → Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus(2017)176 cited
- → How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial(2019)118 cited
- → Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure(2021)65 cited
- → Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation(2021)60 cited
- → Experience with belatacept rescue therapy in kidney transplant recipients(2016)58 cited